Scarletred is honored to be featured in the nationwide Rare Diseases. The article highlights how Scarletred®Vision, our certified smartphone-based medical software, is redefining dermatology and improving care for rare skin conditions such as Epidermolysis bullosa (EB).

For more than a decade, Scarletred has been advancing validated AI-driven innovation to:

• Deliver objective, standardized lesion assessment
• Reduce the need for frequent and painful hospital visits
• Support physicians and researchers with reliable clinical data for treatment evaluation and clinical trials

Already used worldwide in over 100 clinical studies, Scarletred®Vision brings dermatology into patients’ homes - making monitoring safer, faster, and more accessible for families and clinicians alike.

As CEO & Founder Dr. Harald Schnidar explains:

Since our founding in 2014, we have pursued a clear goal: to make dermatological documentation and assessment more objective, standardized, and efficient, and to support the development of new therapies. For this, we develop mobile technologies that reach and connect patients and physicians worldwide.

With trusted partners across academia, BioPharma, and patient organizations, Scarletred continues to set new standards in AI-powered rare disease care.

‍
Read the article online here